Is There a Need to Increase the Dose of Efavirenz During Concomitant Rifampicin-Based Antituberculosis Therapy in Sub-Saharan Africa? The HIV-TB Pharmagene Study

References

• Semvua HH , KibikiGS . AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus . BMC Res. Notes4 , 511 ( 2011 ).
   PubMedGoogle Scholar
• Yimer G , UedaN , HabtewoldAet al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB–HIV infected patients . PLoS ONE6 ( 12 ), e27810 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mugusi S , NgaimisiE , JanabiMet al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania . PLoS ONE7 ( 7 ), e40180 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Habtewold A , AmogneW , MakonnenEet al. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients . Pharmacogenomics J.13 ( 6 ), 484 – 489 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Habtewold A , AmogneW , MakonnenEet al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients . J. Antimicrob. Chemother.66 ( 10 ), 2350 – 2361 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ngaimisi E , MugusiS , MinziOet al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis . Clin. Pharmacol. Ther.90 ( 3 ), 406 – 413 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ngaimisi E , MugusiS , MinziOMet al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients . Clin. Pharmacol. Ther.88 ( 5 ), 676 – 684 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Best BM , GoicoecheaM . Efavirenz – still first-line king?Expert Opin. Drug Metab. Toxicol.4 ( 7 ), 965 – 972 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Maggiolo F . Efavirenz: a decade of clinical experience in the treatment of HIV . J. Antimicrob. Chemother.64 ( 5 ), 910 – 928 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Manosuthi W , KiertiburanakulS , SungkanuparphSet al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results . AIDS20 ( 1 ), 131 – 132 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lopez-Cortes LF , Ruiz-ValderasR , VicianaPet al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis . Clin. Pharmacokinet.41 ( 9 ), 681 – 690 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Yenny Nafrialdi , DjoerbanZet al. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers . Int. J. Clin. Pharmacol. Ther.49 ( 2 ), 162 – 168 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rekic D , RoshammarD , MukonzoJet al. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype . Br. J. Clin. Pharmacol.71 ( 4 ), 536 – 543 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mukonzo JK , OkweraA , NakasujjaNet al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study . BMC Infect. Dis.13 , 261 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cohen K , GrantA , DandaraCet al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516 G>T polymorphism on efavirenz concentrations in adults in South Africa . Antivir. Ther.14 ( 5 ), 687 – 695 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ren Y , NuttallJJ , EleyBSet al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis . J. Acquir. Immune Defic. Syndr.50 ( 5 ), 439 – 443 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gengiah TN , HolfordNH , BothaJHet al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis . Eur. J. Clin. Pharmacol.68 ( 5 ), 689 – 695 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kwara A , LarteyM , SagoeKWet al. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy . AIDS25 ( 3 ), 388 – 390 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Rosenkranz SL , LuD , MarzanFet al. Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study . Clin. Infect. Dis. ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Orrell C , CohenK , ConradieFet al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir. Ther. 16 ( 4 ), 527 – 534 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ngaimisi E , HabtewoldA , MinziOet al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations . PLoS ONE8 ( 7 ), e67946 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Thompson MA , AbergJA , HoyJFet al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel . JAMA308 ( 4 ), 387 – 402 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug administration . Sustiva labeling update/dosing adjustment with rifampin . http://archive.today/Qqaq6 .
   Google Scholar
• Pozniak AL , CoyneKM , MillerRFet al. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011 . HIV Med.12 ( 9 ), 517 – 524 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lopez-Cortes LF , Ruiz-ValderasR , Marin-NieblaAet al. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations . J. Acquir. Immune Defic. Syndr.39 ( 5 ), 551 – 556 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Burhenne J , MattheeAK , PasakovaIet al. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment . Antimicrob. Agents Chemother.54 ( 10 ), 4185 – 4191 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use ofantiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services . http://aidsinfo.nih.gov/contentfiles .
   Google Scholar
• Yimer G , AmogneW , HabtewoldAet al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study . Pharmacogenomics J.12 ( 6 ), 499 – 506 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mukonzo JK , NanziguS , RekicDet al. HIV/AIDS Patients display lower relative bioavailability of efavirenz than healthy subjects . Clin. Pharmacokinet.50 ( 8 ), 531 – 540 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mukonzo JK , NanziguS , WaakoPet al. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure . Pharmacogenomics15 ( 11 ), 1423 – 1435 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Friedland G , KhooS , JackCet al. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV . J. Antimicrob. Chemother.58 ( 6 ), 1299 – 1302 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mcilleron HM , SchomakerM , RenYet al. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype . AIDS27 ( 12 ), 1933 – 1940 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kwara A , RamachandranG , SwaminathanS . Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all . Expert Opin. Drug Metab. Toxicol.6 ( 1 ), 55 – 68 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ramachandran G , Hemanth KumarAK , RajasekaranSet al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India . Antimicrob. Agents Chemother.53 ( 3 ), 863 – 868 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Manosuthi W , SukasemC , LueangniyomkulAet al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients . Antimicrob. Agents Chemother.57 ( 2 ), 1019 – 1024 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Group ES , PulsR , AminJet al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial . Lancet383 ( 9927 ), 1474 – 1482 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mukonzo JK , OwenJS , Ogwal-OkengJet al. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes . PLoS ONE9 ( 1 ), e86919 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ogburn ET , JonesDR , MastersARet al. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation . Drug Metab. Dispos.38 ( 7 ), 1218 – 1229 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Court MH , AlmutairiFE , GreenblattDJet al. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6 . Antimicrob. Agents Chemother.58 ( 7 ), 4145 – 4152 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wen X , WangJS , NeuvonenPJet al. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6,2C19 and 3A4 isoforms in human liver microsomes . Eur. J. Clin. Pharmacol.57 ( 11 ), 799 – 804 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Wanchu A , KuttiattVS , SharmaAet al. CD4 cell count recovery in HIV/TB co-infected patients versus TB uninfected HIV patients . Indian J. Pathol. Microbiol.53 ( 4 ), 745 – 749 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Yimer G , GryM , AmogneWet al. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients . PLoS ONE9 ( 4 ), e94271 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mukonzo J , RoshammarD , WaakoPet al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans . Br. J. Clin. Pharmacol.68 ( 5 ), 690 – 699 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Aklillu E , DandaraC , BertilssonLet al. Pharmacogenetics of cytochrome P450s in African populations: clinical and molecular evolutionary implications . In : Pharmacogenomics in Admixed Populations.Suarez-KurtzG ( Ed. ). Landes Bioscience , TX, USA , 99 – 119 ( 2007 ).
   Google Scholar